Literature DB >> 10375541

Binding of a dimeric derivative of vancomycin to L-Lys-D-Ala-D-lactate in solution and at a surface.

J Rao1, L Yan, J Lahiri, G M Whitesides, R M Weis, H S Warren.   

Abstract

BACKGROUND: The emergence of bacteria that are resistant to vancomycin (V), a glycopeptide antibiotic, results from the replacement of the carboxy-terminal D-Ala-D-Ala of bacterial cell wall precursors by D-Ala-D-lactate. Recently, it has been demonstrated that covalent dimeric variants of V are active against vancomycin-resistant enterococci (VRE). To study the contribution of divalency to the activities of these variants, we modeled the interactions of V and a dimeric V with L-Lys-D-Ala-D-lactate, an analog of the cell-wall precursors of the vancomycin-resistant bacteria.
RESULTS: A dimeric derivative of V (V-Rd-V) was found to be much more effective than V in inhibiting the growth of VRE. The interactions of V and V-Rd-V with a monomeric lactate ligand - diacetyl-L-Lys-D-Ala-D-lactate (Ac2KDADLac) - and a dimeric derivative of L-Lys-D-Ala-D-lactate (Lac-R'd-Lac) in solution have been examined using isothermal titration calorimetry and UV spectroscopy titrations; the results reveal that V-Rd-V binds Lac-R'd-Lac approximately 40 times more tightly than V binds Ac2KDADLac. Binding of V and of V-Rd-V to Nalpha-Ac-L-Lys-D-Ala-D-lactate presented on the surface of mixed self-assembled monolayers (SAMs) of alkanethiolates on gold indicates that the apparent off-rate for dissociation of V-Rd-V from the surface is much slower than that of V from the same surface.
CONCLUSIONS: The results are compatible with the hypothesis that divalency is responsible for tight binding, which correlates with small values of minimum inhibitory concentrations of V and V-Rd-V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375541     DOI: 10.1016/S1074-5521(99)80047-7

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  7 in total

1.  The effect of environment on the recognition and binding of vancomycin to native and resistant forms of lipid II.

Authors:  ZhiGuang Jia; Megan L O'Mara; Johannes Zuegg; Matthew A Cooper; Alan E Mark
Journal:  Biophys J       Date:  2011-12-07       Impact factor: 4.033

2.  Host-guest chemistry of the peptidoglycan.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

Review 3.  Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.

Authors:  Daina Zeng; Dmitri Debabov; Theresa L Hartsell; Raul J Cano; Stacy Adams; Jessica A Schuyler; Ronald McMillan; John L Pace
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

4.  Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate.

Authors:  Lan Chen; Deborah Walker; Binyuan Sun; Yanan Hu; Suzanne Walker; Daniel Kahne
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-24       Impact factor: 11.205

5.  Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus.

Authors:  Sung Joon Kim; Manmilan Singh; Jacob Schaefer
Journal:  J Mol Biol       Date:  2009-06-16       Impact factor: 5.469

Review 6.  Using self-assembled monolayers to model the extracellular matrix.

Authors:  Milan Mrksich
Journal:  Acta Biomater       Date:  2009-01-27       Impact factor: 8.947

7.  Polymerizable vancomycin derivatives for bactericidal biomaterial surface modification: structure-function evaluation.

Authors:  McKinley C Lawson; Richard Shoemaker; Kevin B Hoth; Christopher N Bowman; Kristi S Anseth
Journal:  Biomacromolecules       Date:  2009-08-10       Impact factor: 6.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.